Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

. 2016 Jun 01 ; 62 (11) : 1380-1389. [epub] 20160308

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid26962078

BACKGROUND: When combined with ceftazidime, the novel non-β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in 1066 men and women with complicated intra-abdominal infections from 2 identical, randomized, double-blind phase 3 studies (NCT01499290 and NCT01500239). METHODS: The primary end point was clinical cure at test-of-cure visit 28-35 days after randomization, assessed by noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in the microbiologically modified intention-to-treat (mMITT) population (in accordance with US Food and Drug Administration guidance), and the modified intention-to-treat and clinically evaluable populations (European Medicines Agency guidance). Noninferiority was considered met if the lower limit of the 95% confidence interval for between-group difference was greater than the prespecified noninferiority margin of -12.5%. RESULTS: Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis populations. Clinical cure rates with ceftazidime-avibactam plus metronidazole and meropenem, respectively, were as follows: mMITT population, 81.6% and 85.1% (between-group difference, -3.5%; 95% confidence interval -8.64 to 1.58); modified intention-to-treat, 82.5% and 84.9% (-2.4%; -6.90 to 2.10); and clinically evaluable, 91.7% and 92.5% (-0.8%; -4.61 to 2.89). The clinical cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was comparable to that with meropenem (mMITT population, 83.0% and 85.9%, respectively) and similar to the regimen's own efficacy against ceftazidime-susceptible infections (82.0%). Adverse events were similar between groups. CONCLUSIONS: Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complicated intra-abdominal infections. Efficacy was similar against infections caused by ceftazidime-susceptible and ceftazidime-resistant pathogens. The safety profile of ceftazidime-avibactam plus metronidazole was consistent with that previously observed with ceftazidime alone. CLINICAL TRIALS REGISTRATION: NCT01499290 and NCT01500239.

Zobrazit více v PubMed

Sartelli M, Viale P, Catena F et al. . 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg 2013; 8:3. PubMed PMC

Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011; 19:588–95. PubMed

Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med 2013; 80:225–33. PubMed PMC

Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010; 23:160–201. PubMed PMC

Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011; 86:250–9. PubMed PMC

Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39:86–9. PubMed

Crandon JL, Schuck VJ, Banevicius MA et al. . Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56:6137–46. PubMed PMC

Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008; 62:1053–6. PubMed

Stachyra T, Pechereau MC, Bruneau JM et al. . Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother 2010; 54:5132–8. PubMed PMC

Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013; 68:1183–92. PubMed

Vazquez JA, Gonzalez Patzan LD, Stricklin D et al. . Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28:1921–31. PubMed

Actavis Inc. Prescribing Information: AVYCAZ (ceftazidime-avibactam) for injection, for intravenous use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494lbl.pdf Accessed 18 March 2015.

Solomkin JS, Ristagno RL, Das AF et al. . Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis 2013; 56:1765–73. PubMed

Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17:873–90. PubMed

Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26. PubMed

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31–41. PubMed

Skrupky LP, Tellor BR, Mazuski JE. Current strategies for the treatment of complicated intraabdominal infections. Expert Opin Pharmacother 2013; 14:1933–47. PubMed

Mohr JFI. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008; 47(suppl 1):S41–51. PubMed

Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 1984; 25:201–4. PubMed PMC

Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993; 37:229–33. PubMed PMC

Merdjan H, Tarral A, Haazen W, Evene E, Robertson M, Sable C. Pharmacokinetics and tolerability of NXL104 in normal subjects and patients with varying degrees of renal insufficiency. Clin Microbiol Infect 2010; 16(suppl 2):S465.

Cubist Pharmaceuticals. US prescribing information: Zerbaxa. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf Accessed 17 March 2015.

Li J, Knebel W, Riggs M, Zhou D, Nichols W, Das S. Population pharmacokinetic modeling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-abdominal Infection (cIAI) [abstract A-634] In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2012.

Li J, Zhou D, Nichols W, Das S. Evaluation of ceftazidime-avibactam (CAZ-AVI) dose regimens for phase III study in patients with different renal function [abstract A-635] In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2012.

Solomkin J, Hershberger E, Miller B et al. . Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462–71. PubMed PMC

Sartelli M, Catena F, Ansaloni L et al. . Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg 2014; 9:37. PubMed PMC

Lucasti C, Hershberger E, Miller B et al. . Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2014; 58:5350–7. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01499290, NCT01500239

Najít záznam

Citační ukazatele

Možnosti archivace